The NMDA-antagonist ketamine is a novel fast-acting antidepressant shown to have therapeutic effects on individuals with treatment-resistant depression. Women are twice as likely to suffer from depression yet the majority of research on the effects of ketamine has focused on males. This research is, therefore, aimed at investigating how ovarian hormones and ketamine interact at a neurobiological level in the brain of female rats.